相关实验视频

Updated: Jun 14, 2025

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

针对COVID-19的Tixagevimab/Cilgavimab 血液病患者的暴露前预防-基于SARS-CoV-2疫苗反应的量身定制方法

Krischan Braitsch¹, Samuel D Jeske², Jacob Stroh¹

¹TUM School of Medicine and Health, Department of Internal Medicine III, University Medical Center, Technical University of Munich, 81675 Munich, Germany.

|August 29, 2024

概括

血性恶性瘤免疫受损患者的提克萨吉维马布/西尔加维马布 (TIX/CGB) 暴露前预防 (PrEP) 显示,无论患者是SARS-CoV-2病毒阴性还是病毒阳性,COVID-19的结果都相似. 这支持TIX/CGB PrEP用于血清阴性个体.

科学领域:

免疫学免疫学免疫学
传染性疾病传染性疾病
血液学血液学血液学

背景情况:

患有血液性恶性瘤的患者面临严重COVID-19的高风险.
提克萨吉维玛布/西尔加维玛布 (TIX/CGB) 单克隆抗体组合提供了针对SARS-CoV-2的暴露前预防 (PrEP).
在免疫功能低下,尤其是血清阳性患者中,COVID-19 PrEP的有效性仍然不清楚.

研究的目的:

评估TIX/CGB PrEP在患有血液病的SARS-CoV-2血阴性患者中的特征和结果.
为了比较TIX/CGB PrEP接受者和未接受治疗的阳性血清患者之间的结果.
评估德国国家指导方针的有效性,建议TIX/CGB PrEP仅用于血清阴性个体.

主要方法:

追溯分析54名SARS-CoV-2病毒阴性血液病患者接受TIX/CGB PrEP.
与125名未经治疗的SARS-CoV-2血清阳性患者血液病的比较.
在12个月内分析COVID-19突破性感染和相关结果.

主要成果:

在血清阴性患者中,TIX/CGB PrEP导致COVID-19突破性感染的比率与未经治疗的血清阳性患者相比 (36%) 相当 (32%).
在两组之间观察到与COVID-19相关的可比结果,包括住院和氧气需求.
在血清阴性和血清阳性队列之间,在疾病类型 (B细胞淋巴瘤与骨髓性疾病) 和先前治疗 (异性干细胞移植) 中发现了显著的差异.

结论:

这项研究支持德国指导方针的量身定制方法,即将TIX/CGB PrEP专用于SARS-CoV-2血清阴性患者.
研究结果表明,TIX/CGB PrEP可以有效地降低脆弱的血清阴性血液病患者的COVID-19严重程度.
结果可能会为未来疾病爆发的策略提供信息,特别是关于资源分配和预防.

关键词:

在 COVID-19 疫情中,这就是为什么PrEP是PrEP.血性恶性瘤血性恶性瘤中和抗体中和抗体.一个小小的小小的小小的小小的

更多相关视频

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...